Technical Analysis for CGEM - Cullinan Management, Inc.

Grade Last Price % Change Price Change
F 22.905 1.53% 0.35
CGEM closed down 3.8 percent on Wednesday, September 22, 2021, on 75 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical CGEM trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness -3.80%
Older End-of-Day Signals for CGEM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Lower Bollinger Band 1 minute ago
Up 2% 1 minute ago
Up 1% 1 minute ago
Down 2 % about 18 hours ago
Fell Below Previous Day's Low about 18 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Cullinan Management, Inc. Description

Cullinan Oncology, LLC, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Its lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. The company's preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell acute lymphoblastic leukemia; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. It has a collaboration agreement with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, LLC was founded in 2016 and is headquartered in Cambridge, Massachusetts.


Sector: Other
Industry: Other
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Solid Tumors Immune System Antibodies Oncology Monoclonal Antibody Cancer Immunotherapy Non Small Cell Lung Cancer Acute Myeloid Leukemia Cell Therapy Tumors Therapies For Cancer Treatment Of Acute Myeloid Leukemia Oncology Therapies B Cell Acute Lymphoblastic Leukemia Preclinical Products

Is CGEM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 59.85
52 Week Low 22.48
Average Volume 235,435
200-Day Moving Average 0.00
50-Day Moving Average 27.10
20-Day Moving Average 27.79
10-Day Moving Average 26.98
Average True Range 1.72
ADX 20.49
+DI 9.91
-DI 33.56
Chandelier Exit (Long, 3 ATRs) 25.18
Chandelier Exit (Short, 3 ATRs) 27.63
Upper Bollinger Bands 31.80
Lower Bollinger Band 23.78
Percent B (%b) -0.15
BandWidth 28.83
MACD Line -0.80
MACD Signal Line -0.04
MACD Histogram -0.7644
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.80
Resistance 3 (R3) 25.02 24.49 24.42
Resistance 2 (R2) 24.49 23.92 24.38 24.30
Resistance 1 (R1) 23.53 23.57 23.27 23.31 24.17
Pivot Point 23.00 23.00 22.87 22.89 23.00
Support 1 (S1) 22.04 22.43 21.78 21.82 20.95
Support 2 (S2) 21.51 22.08 21.40 20.82
Support 3 (S3) 20.55 21.51 20.70
Support 4 (S4) 20.33